Cat. No.: HY-N0600

Ginsenoside F3

Avis client

Based on 1 Customer Validation

Ginsenoside F3 is a saponin extracted from the leaves of Panax ginseng with immunoenhancing and antitumor immunostimulatory activities. Ginsenoside F3 upregulates RIPOR2 with a K_d value of 3.77 μM. Ginsenoside F3 enhances NF‑κB activation, upregulates T‑bet and downregulates GATA‑3, increases the production of IL‑2 and IFN‑γ, decreases the production of IL‑4 and IL‑10, reverses CD8⁺ T‑cell exhaustion, restores cytokine secretion, and enhances antitumor immunity in a mouse non‑small cell lung cancer model. Ginsenoside F3 can be used for the research of non-small cell lung cancer.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.84%
CAS No.: 62025-50-7
Formule: C₄₁H₇₀O₁₃
Masse moléculaire:770.99

Stockage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Ginsenoside F3 Chemical Structure

CAS No.: 62025-50-7

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Solvant et solubilité
- In Vitro
- In Vivo
Pureté et documentation
Références
Help & FAQs
Bioz

Activité biologique

Description

IC₅₀ & Target^[2]

IL-2

IL-4

IL-10

NF-κB

Voir tous les produits spécifiques à Isoform Interleukin Related :

Voir tous les produits spécifiques à Isoform NF-κB :

In Vitro

Ginsenoside F3 (0.1-100 μmol/L; 72 h) significantly enhances Concanavalin A (HY-P2149)-induced murine spleen cell proliferation, with the maximal 87.2% increase occurring at 10 μmol/L^[1].
Ginsenoside F3 (0.1-100 μmol/L; 48 or 72 h) increases Concanavalin A-induced IL-2 and IFN-γ production and decreases ConA-induced IL-4 and IL-10 production in murine spleen cells, with maximal effects at 10 μmol/L^[1].
Ginsenoside F3 (0.1-100 μmol/L; 10 h) upregulates Concanavalin A-induced IFN-γ and T-bet mRNA expression and downregulates ConA-induced IL-4 and GATA-3 mRNA expression in murine spleen cells^[1].
Ginsenoside F3 (10 μmol/L; 1 h) enhances Concanavalin A-induced NF-κB DNA binding activity in murine spleen cells^[1].
Ginsenoside F3 directly binds to RIPOR2 with a binding affinity of 3.77 μM^[2].
Ginsenoside F3 (0.1-10 μM; day 4 and day 6 of chronic stimulation) dose-dependently reduces the frequency of PD-1⁺ TIM-3⁺ exhausted primary mouse CD8⁺ T cells under chronic anti-CD3 stimulation, and restores RIPOR2 expression in these cells^[2].
Ginsenoside F3 (0.1-10 μM; 6 days) dose-dependently restores TNF-α and IFN-γ cytokine production in exhausted primary mouse CD8⁺ T cells cultured under chronic anti-CD3 stimulation for 6 days^[2].
Ginsenoside F3 (1-10 μM; 48 h) significantly promotes the proliferation of Jurkat T cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[2]

Cell Line:

Jurkat T cells
Concentration:

0.1, 1, 10, 100 μM
Incubation Time:

48 h
Result:

Significantly increased Jurkat T cell proliferation at 1 and 10 μM, with the 10 μM dose yielding the largest increase (~20% higher absorbance than untreated controls).
Showed a trend toward increased proliferation at 0.1 μM.
Showed reduced proliferation relative to the 10 μM dose but remained above control levels at 100 μM.

Cell Viability Assay^[2]

Cell Line:

H1299, A549, and Lewis lung carcinoma (LLC) cells
Concentration:

0.1, 1, 10, 100 μM
Incubation Time:

24, 48, or 72 h
Result:

Showed no significant cytotoxic effect on H1299, A549, or LLC cells at concentrations ≤ 10 μM at any incubation time.
Showed a modest inhibitory effect on A549 and H1299 cells (≤ 20% reduction in viability) after 72 h at 100 μM.
Showed no significant effect on LLC cells at any dose or time point.

In Vivo

Ginsenoside F3 (5 mg/kg; i.p.; daily; 28 days) alone reduces NSCLC tumor burden and increases intratumoral CD4⁺ T cell infiltration, and synergizes with anti-PD-1 therapy to further reduce tumor burden and enhance CD8⁺ T cell infiltration in the tumor microenvironment^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C57BL/6 J mice (male, 6-8 weeks old, 20-30 g, intravenous tail vein injection of 4 × 10⁶ LLC cells)^[2]
Dosage:

5 mg/kg
Administration:

i.p.; daily; 28 days
Result:

Reduced mean lung tumor weight to 0.457 g, compared to 0.907 g in the model group.
Increased the proportion of CD4⁺ T cells among tumor-infiltrating CD3⁺ lymphocytes to 28.1%, compared to 19.5% in the model group.

Chemical Information

CAS No. 62025-50-7
Appearance Solid
Masse moléculaire 770.99
Formule C₄₁H₇₀O₁₃
Color White to off-white
SMILES

C[C@]([C@@](C[C@H]1O)([H])[C@]2(CC[C@@H]3O)C)(C[C@H](O)[C@@]2([H])C3(C)C)[C@]4([C@@]1([H])[C@]([C@@](CC/C=C(C)/C)(C)O[C@@H]([C@@H]([C@@H](O)[C@@H]5O)O)O[C@@H]5CO[C@H](OC[C@H](O)[C@@H]6O)[C@@H]6O)([H])CC4)C
Structure Classification
- Terpenoids
- Triterpenes
Initial Source
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvant et solubilité

In Vitro:

DMSO : 100 mg/mL (129.70 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.2970 mL

6.4852 mL

12.9703 mL

5 mM

0.2594 mL

1.2970 mL

2.5941 mL

10 mM

0.1297 mL

0.6485 mL

1.2970 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (3.24 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (3.24 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (3.24 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (287 KB)
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Yu JL. Immunoenhancing activity of protopanaxatriol-type ginsenoside-F3 in murine spleen cells. Acta Pharmacol Sin. 2005;25(12):1671-6.

[2]. Jiang M, et al. Ginsenoside F3 alleviates T cell exhaustion via RIPOR2-mediated immunometabolic reprogramming to potentiate anti-PD-1 therapy. Phytomedicine. 2026;150:157649. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.2970 mL	6.4852 mL	12.9703 mL	32.4258 mL
	5 mM	0.2594 mL	1.2970 mL	2.5941 mL	6.4852 mL
	10 mM	0.1297 mL	0.6485 mL	1.2970 mL	3.2426 mL
	15 mM	0.0865 mL	0.4323 mL	0.8647 mL	2.1617 mL
	20 mM	0.0649 mL	0.3243 mL	0.6485 mL	1.6213 mL
	25 mM	0.0519 mL	0.2594 mL	0.5188 mL	1.2970 mL
	30 mM	0.0432 mL	0.2162 mL	0.4323 mL	1.0809 mL
	40 mM	0.0324 mL	0.1621 mL	0.3243 mL	0.8106 mL
	50 mM	0.0259 mL	0.1297 mL	0.2594 mL	0.6485 mL
	60 mM	0.0216 mL	0.1081 mL	0.2162 mL	0.5404 mL
	80 mM	0.0162 mL	0.0811 mL	0.1621 mL	0.4053 mL
	100 mM	0.0130 mL	0.0649 mL	0.1297 mL	0.3243 mL

Keywords

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Ginsenoside F3

Immunology/Inflammation Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Aging Compound Library

Antioxidant Compound Library

Glycoside Compound Library

Oxygen Sensing Compound Library

Medicine Food Homology Compound Library

Terpenoids Library

Pyroptosis Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Food-Sourced Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Pain-Related Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Autoimmune Disease Compound Library

Immunopotentiator Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Natural Product Diversity Scaffold Library

Tonifying Traditional Chinese Medicine Monomer Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Voir tous les produits spécifiques à Isoform Interleukin Related

Voir tous les produits spécifiques à Isoform NF-κB

Activité biologique

Chemical Information

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Ginsenoside F3 Related Classifications

Cat. No.: HY-N0600